6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and LantusĀ® both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension Period
Insulin Glargin 300 U/ml
NCT01499082, EudraCT2010-023769-23
Diabetes Mellitus Type 2
Phase 3
Datasets and document are available as per Sanofi Policy and criteria. 12-month datasets will be made available.There are 3 clinical study reports for the main 6 months, for the Substudy Comparing Adaptable Dosing Intervals with Fixed Dosing Intervals and for the 12 months
August 2015